Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Benitec Biopharma (BNTC) Share-based Compensation (2019 - 2025)

Benitec Biopharma's Share-based Compensation history spans 7 years, with the latest figure at $402000.0 for Q1 2025.

  • For Q1 2025, Share-based Compensation rose 109.38% year-over-year to $402000.0; the TTM value through Mar 2025 reached $4.4 million, up 780.52%, while the annual FY2024 figure was $830000.0, 83.63% up from the prior year.
  • Share-based Compensation for Q1 2025 was $402000.0 at Benitec Biopharma, down from $3.1 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $3.1 million in Q4 2024 and bottomed at -$48000.0 in Q4 2022.
  • The 5-year median for Share-based Compensation is $235000.0 (2021), against an average of $390647.1.
  • The largest annual shift saw Share-based Compensation tumbled 120.08% in 2022 before it soared 3274.19% in 2024.
  • A 5-year view of Share-based Compensation shows it stood at $239000.0 in 2021, then crashed by 120.08% to -$48000.0 in 2022, then soared by 293.75% to $93000.0 in 2023, then skyrocketed by 3274.19% to $3.1 million in 2024, then tumbled by 87.19% to $402000.0 in 2025.
  • Per Business Quant, the three most recent readings for BNTC's Share-based Compensation are $402000.0 (Q1 2025), $3.1 million (Q4 2024), and $435000.0 (Q3 2024).